SOPHiA GENETICS SA - Ordinary Shares (SOPH)

Competitors to SOPHiA GENETICS SA - Ordinary Shares (SOPH)

Freenome Holdings, Inc.

Freenome focuses on using artificial intelligence to detect early signs of cancer through multiomics data analysis. The company competes with SOPHiA GENETICS by targeting similar markets that aim to enhance diagnostics and improve patient outcomes. While SOPHiA leverages shared genomic data to create insights for various diseases and conditions, Freenome's unique offering lies in its AI-driven systemic approach and liquid biopsy technology. This creates a direct competitive landscape, but SOPHiA's established platform and diverse partnerships give it a competitive edge in broader applications of genomic data.

GRAIL, Inc.

GRAIL is focused on early cancer detection through advanced genomic testing, and it competes with SOPHiA GENETICS by providing innovative multi-cancer early detection tests. While both companies are aligned in similar goals toward improving cancer diagnostics, GRAIL's distinct focus on early-stage detection offers a competitive specificity that attracts attention in the oncology space. Conversely, SOPHiA establishes itself with a broader data-driven approach to various health conditions, thus affording it an advantage in versatility and applicability across multiple diseases.

Guardant Health, Inc. 

Guardant Health specializes in non-invasive cancer detection and monitoring through its liquid biopsy approach. SOPHiA GENETICS competes with Guardant by also offering genomic data analysis tools that can be used across multiple tumor types. While both companies operate in the oncology space, Guardant has a competitive advantage with its specific focus on blood-based testing solutions and a strong reputation among oncologists and healthcare providers. However, SOPHiA's cloud-based platform provides broader utility for various genomic applications beyond oncology, which can be seen as a strength in diversifying its market approach.

Illumina, Inc. 

Illumina is a leader in genomic sequencing technologies and competes with SOPHiA GENETICS primarily through its development and provision of advanced sequencers and associated data analysis tools. While SOPHiA focuses on democratizing data-driven medicine through its cloud-based data sharing and analytics platform, Illumina has a strong foothold in the DNA sequencing market due to its innovative products and established customer base in research and clinical settings. Illumina's broad portfolio of high-performance sequencing systems and reagents gives it a significant market edge, positioning it as a leader in genomics.

Thermo Fisher Scientific Inc. 

Thermo Fisher Scientific is a dominant player in the life sciences field, offering a diverse product range that includes reagents, instruments, and consumables for genomic analysis. SOPHiA GENETICS competes with Thermo Fisher by focusing on its unique analytical platform that allows for collaborative genomic data analysis. While Thermo Fisher holds an advantage with its extensive distribution, established reputation, and wide array of integrated solutions, SOPHiA’s targeted approach and emphasis on data sharing could potentially enable it to carve out a significant niche in precision medicine and diagnostics.